MORPHOSYS AG O.N. news, videos and press releases - Page 5
For more news please use our advanced search feature.
MORPHOSYS AG O.N. - More news...
MORPHOSYS AG O.N. - More news...
- DGAP-News: MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
- DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
- DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
- DGAP-News: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
- DGAP-News: MorphoSys AG: Corporate Calendar 2022
- Corporate Calendar 2022
- MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results
- DGAP-News: MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results
- DGAP-News: MorphoSys Announces Departure of Roland Wandeler
- MorphoSys Announces Departure of Roland Wandeler
- DGAP-News: MorphoSys presents interim results from M-PLACE study with felzartamab during American Society of Nephrology Annual Meeting
- MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting
- DGAP-News: MorphoSys to present MANIFEST and RE-MIND2 data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
- MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
- DGAP-News: MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021
- MorphoSys AG Announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the Upcoming Conference Call on November 11, 2021
- DGAP-News: MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
- MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
- DGAP-News: MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease
- MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease
- DGAP-News: MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory DLBCL
- DGAP-News: Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- DGAP-News: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
- MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
- MorphoSys AG Reports Second Quarter and First Half 2021 Results
- DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2021 Results
- DGAP-Adhoc: Ad-hoc: MorphoSys AG to update financial guidance for 2021 and reduce financial liabilities
- MorphoSys AG to Update Financial Guidance for 2021 and Reduce Financial Liabilities
- DGAP-News: Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021
- Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021
